Concentration Of Business Risk

3 Months Ended

Mar. 31, 2012

Concentration Of Business Risk [Abstract]

Concentration Of Business Risk

8. Concentration of Business Risk

A relatively small number of customers and collaboration partners historically have accounted for a significant percentage of the Company's revenue. Revenue from the Company's largest customer, Danisco, represented 43% and 56% of total revenue from continuing operations for the three months ended March 31, 2012 and 2011. Accounts receivable from this one customer comprised approximately 66% of accounts receivable at March 31, 2012 and 78% at December 31, 2011.

Revenue by geographic area was as follows (in thousands):

	For the Three Months Ended March 31,
	2012		2011
North America	$	6,463	$	4,195
South America		2,388		2,116
Europe		7,876		6,769
Asia		502		316
	$	17,229	$	13,396

After the Company's sale of assets related to its oilseed processing product line to DSM, the Company manufactures and sells enzymes primarily within four main product lines. The historical numbers include the oilseed processing product line. The animal health and nutrition product line primarily includes the Phyzyme^® XP phytase enzyme and from time to time toll manufacturing of other products in this market and the grain processing product line includes Fuelzyme^® alpha-amylase, Veretase^® alpha-amylase, Xylathin™ xylanase and DELTAZYM^® GA L-E5 gluco-amylase enzymes.

The following table sets forth product revenues by individual product line (in thousands):

	Three Months Ended March 31,
	2012		% of Product Revenue			2011		% of Product Revenue
Product revenues:
Animal health and nutrition	$	7,416		63	%	$	8,075		62	%
Grain processing		3,585		31	%		3,894		30	%
Oilseed processing (1)		579		5	%		983		8	%
All other products		141		1	%		80		0	%
Total product revenue	$	11,721		100	%	$	13,032		100	%

(1) As the Company will continue to provide manufacturing services for the products sold and licensed to DSM, all future revenue will be classified as contract manufacturing revenue within the Company's product revenue line item on the condensed consolidated statements of operations. All historical amounts related to the oilseed processing business will continue to be shown as commercial product revenue.

The Company manufactures most of its enzyme products through a manufacturing facility in Mexico City, owned by Fermic. The carrying value of property and equipment held at Fermic reported on the Company's consolidated balance sheets totaled approximately $0.9 million and $1.1 million at March 31, 2012 and at December 31, 2011.